Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Predictors of Response to Fremanezumab in Migraine Patients with at Least Three Previous Preventive Failures: Post Hoc Analysis of a Prospective, Multicenter, Real-World Greek Registry
Andreas A. Argyriou, Emmanouil V. Dermitzakis, Georgia Xiromerisiou, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 9, pp. 3218-3218
Open Access | Times Cited: 10

Showing 10 citing articles:

Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world
Edoardo Caronna, Victor J Gallardo, Gabriella Egeo, et al.
Journal of Neurology Neurosurgery & Psychiatry (2024), pp. jnnp-333295
Closed Access | Times Cited: 18
Results of a Web-Based Survey on 2565 Greek Migraine Patients in 2023: Demographic Data, Imposed Burden and Satisfaction to Acute and Prophylactic Treatments in the Era of New Treatment Options
Emmanouil V. Dermitzakis, Andreas A. Argyriou, Konstantinos Bilias, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 10, pp. 2768-2768
Open Access | Times Cited: 4
Real-World Lessons with Fremanezumab as the Third Available CGRP Monoclonal Antibody in a Third-Level Hospital: Focus on the Factors Predicting Response
Marcos Polanco-Fernandez, Gabriel Gárate, Julia Sánchez-Gudín, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 4, pp. 1054-1054
Open Access
Nine-Month Continuous Fremanezumab Prophylaxis on the Response to Triptans and Also on the Incidence of Triggers, Hypersensitivity and Prodromal Symptoms of Patients with High-Frequency Episodic Migraine
Emmanouil V. Dermitzakis, Michail Vikelis, Georgia Xiromerisiou, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 2, pp. 386-386
Open Access | Times Cited: 3
Effects of Fremanezumab on Psychiatric Comorbidities in Difficult-to-Treat Patients with Chronic Migraine: Post Hoc Analysis of a Prospective, Multicenter, Real-World Greek Registry
Michail Vikelis, Emmanouil V. Dermitzakis, Georgia Xiromerisiou, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 13, pp. 4526-4526
Open Access | Times Cited: 9
Treatment Outcome After Switching From Galcanezumab to Fremanezumab in Patients With Migraine
Michelle Sojung Youn, Namoh Kim, Mi Ji Lee, et al.
Journal of Clinical Neurology (2024) Vol. 20, Iss. 3, pp. 300-300
Open Access | Times Cited: 2
Real-world efficacy and tolerability of fremanezumab in adults with chronic migraine: a 3-month, single-center, prospective, observational study
Christopher Kjær Cullum, Basit Ali Chaudhry, Thien Phu, et al.
Frontiers in Neurology (2023) Vol. 14
Open Access | Times Cited: 6
Are we closer to achieving precision medicine for migraine treatment? A narrative review
Keiko Ihara, Francesco Casillo, Ahmed Dahshan, et al.
Cephalalgia (2024) Vol. 44, Iss. 9
Closed Access | Times Cited: 1
High-frequency episodic migraine: Time for its recognition as a migraine subtype?
Francescantonio Cammarota, Roberto De Icco, Gloria Vaghi, et al.
Cephalalgia (2024) Vol. 44, Iss. 10
Closed Access | Times Cited: 1
Fremanezumab in real-life clinical practice: specialized headache center experience
Yu. É. Azimova, K. V. Skorobogatikh, V. В. Osipova, et al.
Neurology neuropsychiatry Psychosomatics (2024) Vol. 16, Iss. 3, pp. 72-78
Open Access
Page 1

Scroll to top